Temodar [temozolomide] and Sutent [sunitinib] as therapy for patients with malignant melanoma, a phase I/II study.
Phase of Trial: Phase I/II
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Sunitinib; Temozolomide
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Feb 2009 Actual patient number (7) added as reported by ClinicalTrials.gov.
- 03 Feb 2009 Planned end date changed from 1 Apr 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.